UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class

Diabetes, obesity & metabolism, 2021-09, Vol.23 (S3), p.30-39

2021

Volltextzugriff (PDF)

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

The lancet. Diabetes & endocrinology, 2017-04, Vol.5 (4), p.251-260

2017

Volltextzugriff (PDF)

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.442-451

2020

Volltextzugriff (PDF)

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

The lancet. Diabetes & endocrinology, 2017-05, Vol.5 (5), p.355-366

2017

Volltextzugriff (PDF)

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Cardiovascular diabetology, 2019-06, Vol.18 (1), p.73-73, Article 73

2019

Volltextzugriff (PDF)

The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease

Atherosclerosis, 2009-02, Vol.202 (2), p.321-329

2009

Volltextzugriff (PDF)

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

Endocrinology and metabolism (Seoul), 2023-02, Vol.38 (1), p.25-33

2023

Volltextzugriff (PDF)

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Diabetes therapy, 2021-01, Vol.12 (1), p.143-157

2021

Volltextzugriff (PDF)

Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy

The New England journal of medicine, 2004-11, Vol.351 (19), p.1952-1961

2004

Volltextzugriff (PDF)

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Cardiovascular diabetology, 2020-09, Vol.19 (1), p.156-156, Article 156

2020

Volltextzugriff (PDF)

Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes

PloS one, 2018-04, Vol.13 (4), p.e0194750-e0194750

2018

Volltextzugriff (PDF)

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

Cardiovascular diabetology, 2023-08, Vol.22 (1), p.1-220, Article 220

2023

Volltextzugriff (PDF)

The endocrine pancreas during exercise in people with and without type 1 diabetes: Beyond the beta-cell

Frontiers in endocrinology (Lausanne), 2022-09, Vol.13, p.981723-981723

2022

Volltextzugriff (PDF)

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Diabetes, obesity & metabolism, 2020-03, Vol.22 (3), p.303-314

2020

Volltextzugriff (PDF)

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation

PloS one, 2016-04, Vol.11 (4), p.e0154229

2016

Volltextzugriff (PDF)

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena

The Lancet (British edition), 2023-08, Vol.402 (10401), p.504-505

2023

Volltextzugriff (PDF)

Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

Diabetes, obesity & metabolism, 2019-03, Vol.21 (3), p.454-466

2019

Volltextzugriff (PDF)

Supplementary Nitric Oxide Donors and Exercise as Potential Means to Improve Vascular Health in People with Type 1 Diabetes: Yes to NO?

Nutrients, 2019-07, Vol.11 (7), p.1571

2019

Volltextzugriff (PDF)

Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial

PloS one, 2014-05, Vol.9 (5), p.e97143-e97143

2014

Volltextzugriff (PDF)

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

BMJ open diabetes research & care, 2023-06, Vol.11 (3), p.e003300

2023

Volltextzugriff (PDF)

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

The New England journal of medicine, 2019-08, Vol.381 (9), p.841-851

2019

Volltextzugriff (PDF)

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

The New England journal of medicine, 2023-07, Vol.389 (4), p.297-308

2023

Volltextzugriff (PDF)

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

Diabetes, obesity & metabolism, 2019-11, Vol.21 (11), p.2450-2458

2019

Volltextzugriff (PDF)

Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study

Diabetes therapy, 2021-03, Vol.12 (3), p.801-811

2021

Volltextzugriff (PDF)

Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply

The New England journal of medicine, 2019-11, Vol.381 (21), p.2076-2077

2019

Volltextzugriff (PDF)

1 – 25 von 330

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(273)
Mit Volltextzugriff
(293)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(218)
Life Sciences & Biomedicine
(205)
Humans
(141)
Diabetes
(92)
Endocrinology & Metabolism
(92)
Male
(77)
Female
(71)
Diabetes Mellitus
(54)
Middle Aged
(51)
Adult
(48)
Biological And Medical Sciences
(42)
Type 2 Diabetes
(42)
Diabetes Mellitus, Type 2 - Drug Therapy
(38)
Insulin
(38)
Aged
(37)
Medical Sciences
(37)
Animals
(33)
Glucagon
(29)
Hypoglycemic Agents - Therapeutic Use
(29)
Type 1 Diabetes
(28)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

EZB Electronic Journals Library
(182)
MEDLINE
(165)
Journals@Ovid Full Text
(141)
Ingenta
(134)
NUS Single-Journal Subscriptions
(79)
IngentaConnect Journals
(64)
Wiley Online Library
(48)
Elsevier ScienceDirect Journals Complete
(46)
Wiley Online Library
(39)
SpringerLink
(36)
Taylor & Francis Journals
(24)
Nexis Uni
(22)
Elsevier Journal Backfiles on ScienceDirect (DFG Nationallizenzen)
(20)
Taylor & Francis
(18)
Taylor & Francis Journals Complete
(16)
Oxford Journals
(16)
Oxford Journals 2020 Medicine
(14)
Nature Journals
(13)
Ebook Central Perpetual and DDA
(9)
eBooks on EBSCOhost
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

Recent developments in GLP‐1RA therapy: A review of the latest evidence of efficacy and safety and differences within the class

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

The biological relevance and measurement of plasma markers of oxidative stress in diabetes and cardiovascular disease

Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond

The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials

Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy

Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials

Heart rate dynamics during cardio-pulmonary exercise testing are associated with glycemic control in individuals with type 1 diabetes

Effect of semaglutide on major adverse cardiovascular events by baseline kidney parameters in participants with type 2 diabetes and at high risk of cardiovascular disease: SUSTAIN 6 and PIONEER 6 post hoc pooled analysis

The endocrine pancreas during exercise in people with and without type 1 diabetes: Beyond the beta-cell

Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials

Molecular Characterisation of Small Molecule Agonists Effect on the Human Glucagon Like Peptide-1 Receptor Internalisation

A new class of glucose-lowering therapy for type 2 diabetes: the latest development in the incretin arena

Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review

Supplementary Nitric Oxide Donors and Exercise as Potential Means to Improve Vascular Health in People with Type 1 Diabetes: Yes to NO?

Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trial

Glucagon-like peptide-1 receptor agonist use is associated with lower blood ferritin levels in people with type 2 diabetes and hemochromatosis: a nationwide register-based study

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

Long‐term efficacy and safety of combined insulin and glucagon‐like peptide‐1 therapy: Evidence from the LEADER trial

Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study

Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply

Suchergebnisse filtern